| 000 | 01902nam a22003377a 4500 | ||
|---|---|---|---|
| 008 | 190314s20162016 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a2168-8184 | ||
| 024 | _a10.7759/cureus.457 [doi] | ||
| 024 | _aPMC4752374 [pmc] | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a26918225 | ||
| 245 | _aExceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report. | ||
| 251 | _aCureus. 8(1):e457, 2016 Jan 12. | ||
| 252 | _aCureus. 8(1):e457, 2016 Jan 12. | ||
| 253 | _aCureus | ||
| 260 | _c2016 | ||
| 260 | _fFY2016 | ||
| 265 | _sepublish | ||
| 266 | _d2019-03-14 | ||
| 520 | _aGastroesophageal adenocarcinomas represent one of the top five most common types of cancer worldwide. Despite significant advancement, it is still not known which first-line chemotherapy option is best matched to an individual patient. The vast advances in molecular biology have led to the discovery of many potential predictive biomarkers, such as HER-2 neu, thymidylate synthase (TS), excision repair cross-complementation group 1 (ERCC1), and topoisomerase-1 (TOPO1). These markers could allow us to select treatment based on an individual's tumor profile, resulting in an improvement of outcome. Our report highlights two patients with metastatic gastric cancer that achieved an exceptional response with traditional therapy and provides insights into the future perspectives of molecular profile-directed chemotherapy. | ||
| 546 | _aEnglish | ||
| 650 | _aPubMed-not-MEDLINE -- Not indexed | ||
| 651 | _aMedStar Medical Group | ||
| 651 | _aWashington Cancer Institute | ||
| 657 | _aCase Reports | ||
| 700 | _aColton, Bradley | ||
| 700 | _aManning, Maria A | ||
| 790 | _aCarroll JE, Colton B, Hartley M, Manning MA, Mikhail S, Salem ME, Smaglo BG, Xiu J | ||
| 856 |
_uhttps://dx.doi.org/10.7759/cureus.457 _zhttps://dx.doi.org/10.7759/cureus.457 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c4122 _d4122 |
||